Novartis AG (NVSN) — Capital Reinvestment Ratio
Novartis AG (NVSN) has a Capital Reinvestment Ratio of 0.22x as of March 2026, meaning it reinvests 0% of its operating cash flow (MX$3.68 Billion) in capital expenditures (MX$807.00 Million). See Novartis AG (NVSN) balance sheet quality index to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Novartis AG Capital Reinvestment Ratio (2014–2025)
This chart tracks Novartis AG's Capital Reinvestment Ratio across 12 annual periods. Check NVSN cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Novartis AG (2014–2025)
Year-by-year Capital Reinvestment Ratio for Novartis AG from 2014 to 2025. For live market cap and broader valuation context, see NVSN market cap overview.
| Year | Reinvestment Ratio | Operating CF (MXN) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.20x | MX$19.14 Billion | MX$3.90 Billion | ▼ -5.9% |
| 2024 | 0.22x | MX$17.62 Billion | MX$3.81 Billion | ▲ +19.6% |
| 2023 | 0.18x | MX$16.02 Billion | MX$2.90 Billion | ▲ +115.1% |
| 2022 | 0.08x | MX$14.24 Billion | MX$1.20 Billion | ▼ -8.0% |
| 2021 | 0.09x | MX$15.07 Billion | MX$1.38 Billion | ▼ -2.1% |
| 2020 | 0.09x | MX$13.65 Billion | MX$1.27 Billion | ▼ -7.7% |
| 2019 | 0.10x | MX$13.62 Billion | MX$1.38 Billion | ▲ +15.2% |
| 2018 | 0.09x | MX$14.27 Billion | MX$1.25 Billion | ▼ -16.3% |
| 2017 | 0.10x | MX$12.62 Billion | MX$1.32 Billion | ▼ -58.2% |
| 2016 | 0.25x | MX$11.47 Billion | MX$2.88 Billion | ▲ +26.1% |
| 2015 | 0.20x | MX$11.90 Billion | MX$2.37 Billion | ▲ +5.4% |
| 2014 | 0.19x | MX$13.90 Billion | MX$2.62 Billion | — |